GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioMark Diagnostics BUX.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.45

—

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

BioMark Diagnostics — daily BUX

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View BioMark Diagnostics on TradingView ↗
Market value
C$47.3m
Last close × shares
Volume
500
Shares, 9 Nov 2026

About BioMark Diagnostics

Its shares trade on Canadian Securities Exchange under the ticker BUX.CN. It has been listed since 3 November 2014. In the fiscal year to 31 March 2026, it reported revenue of C$59,787 and a net loss of C$1.5m. At that date it held total assets of C$1.9m and shareholders' equity of C$331,063.

BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2014-11-03. The firm is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The company has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

Figures and description from our data supplier, not checked against the company's own report.

More about BioMark Diagnostics →

Latest on BioMark Diagnostics

Our reporting

We have not reported on BioMark Diagnostics yet.

Other N/A listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is BioMark Diagnostics's ticker?

BioMark Diagnostics trades as BUX.CN on Canadian Securities Exchange, under ISIN CA09073K1084.

What was BioMark Diagnostics's last closing price?

0.45 on 9 Nov 2026. The figure is in CAD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.